In 2011 PulmCCM reported the findings of the phase 2 TOMORROW study, showing Boehringer Ingelheim's tyrosine kinase inhibitor code-named BIBF 1120 reduced lung function decline and prevented exacerbations in people with idiopathic pulmonary fibrosis (IPF). At the 2014 American Thoracic Society annual meeting and in the
Nintedanib protects lung function, prevents exacerbations of idiopathic pulmonary fibrosis (INPULSIS)
Nintedanib protects lung function, prevents…
Nintedanib protects lung function, prevents exacerbations of idiopathic pulmonary fibrosis (INPULSIS)
In 2011 PulmCCM reported the findings of the phase 2 TOMORROW study, showing Boehringer Ingelheim's tyrosine kinase inhibitor code-named BIBF 1120 reduced lung function decline and prevented exacerbations in people with idiopathic pulmonary fibrosis (IPF). At the 2014 American Thoracic Society annual meeting and in the